Business Context and Reporting Period
Company: Arcturus Therapeutics Holdings Inc. (ARCT)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Arcturus is a messenger RNA (mRNA) medicines company focused on liver and respiratory rare disease therapeutics and vaccines. Key assets include the self-amplifying mRNA (sa-mRNA) vaccine KOSTAIVE (approved in Japan, EU, and UK) and internal pipeline candidates ARCT-032 (Cystic Fibrosis) and ARCT-810 (Ornithine Transcarbamylase deficiency). The company relies heavily on a strategic collaboration with CSL Seqirus for vaccine commercialization.
Key Financial Metrics
| Metric (in millions) | 2025 | 2024 |
|---|---|---|
| Total Revenue | $82.0 | $152.3 |
| Net Loss | $(65.8) | $(80.9) |
| Net Loss Per Share | $(2.40) | $(3.00) |
| Cash and Cash Equivalents | $230.9 | $237.0 |
| Accumulated Deficit | $(514.6) | $(448.8) |
| Operating Cash Flow | $(74.3) | $(59.7) |
Revenue Composition (2025): Collaboration revenue was $67.2 million (82% from CSL Seqirus) and Grant revenue was $14.8 million (primarily from BARDA and Gates Foundation).
Operating Expenses: Total operating expenses were $158.3 million, a 36% decrease from 2024, driven by reduced R&D spend on the LUNAR-COVID program as it transitioned to commercialization.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 46% to $82.0 million, primarily due to a $72.2 million decrease in collaboration revenue from CSL Seqirus. This was driven by lower milestone achievements ($33.1 million decrease) and reduced commercial supply agreement revenue.
- Improved Loss Profile: Net loss narrowed by $15.2 million to $65.8 million, aided by a significant reduction in R&D expenses ($82.9 million decrease) and lower share-based compensation.
- Liquidity Position: Cash balance remained relatively stable at $230.9 million. The company terminated its Wells Fargo credit agreement in December 2025, releasing $55.0 million of previously restricted cash.
- Regulatory Milestones: KOSTAIVE received approval in the European Commission (Feb 2025) and the UK (Jan 2026). However, the FDA indefinitely delayed the U.S. Biologics License Application (BLA) in October 2025, citing new regulatory requirements for clinical endpoint efficacy data.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary
Management expects to continue incurring losses for the foreseeable future. Current cash resources ($230.9 million) are deemed sufficient to fund operations for at least the next 12 months. Future capital requirements will depend on clinical trial progress and regulatory approvals. The company plans to initiate a 12-week safety and efficacy study for ARCT-032 (CF) in the first half of 2026.
Key Risks and Contingencies
- CSL Seqirus Collaboration Risk: In February 2026, CSL Limited reported a $430 million accounting write-down attributable to the Arcturus collaboration, citing declining COVID-19 disease burden and onerous U.S. regulatory requirements. Arcturus initiated arbitration against CSL Seqirus in May 2025 regarding a milestone payment triggered by EU approval.
- U.S. Regulatory Hurdles: The FDA's requirement for additional clinical endpoint efficacy data for KOSTAIVE has indefinitely delayed U.S. market entry, significantly impacting potential revenue and commercialization timelines.
- Legal Proceedings: Arcturus filed a lawsuit in September 2025 against AbbVie and Capstan Therapeutics alleging trade secret misappropriation and breach of contract.
- Going Concern: While currently funded for 12 months, the company will require additional capital to advance its pipeline and commercialize products. Failure to secure funding could force scaling back of operations.
Investor Verification Checklist
- CSL Arbitration Status: Verify the outcome of the arbitration regarding the EU milestone payment and the impact of CSL's $430 million write-down on future collaboration support.
- FDA Pathway for KOSTAIVE: Confirm the specific clinical trial design and timeline required to satisfy the FDA's new efficacy data requirements for U.S. approval.
- ARCT-032 Phase 2 Data: Review the full results of the Phase 2 Cystic Fibrosis study, specifically regarding mucus burden reduction and safety in Class I mutation patients.
- Capital Raise Plans: Assess the company's strategy for raising additional capital beyond the current 12-month runway, given the reduced revenue from CSL.
- Legal Exposure: Monitor the progress of the trade secret lawsuit against AbbVie/Capstan and potential counterclaims.